Europe
This year marked yet another series of interesting, exciting and occasionally puzzling stories coming out of the biopharma industry. Our breaking news writers, Alex Keown and Mark Terry, picked their top 10 stories of the year.
Companies from across the globe provide updates on their business and pipeline progress.
The future of the atopic dermatitis space is going to be a competitive one. Multiple assets are in line to be submitted for regulatory approval and will, if approved, challenge the leading market share currently held by Regeneron and Sanofi’s Dupixent.
Specifically, it was approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.
The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.
Sarepta Therapeutics and Roche inked a licensing deal that gives Roche exclusive commercial rights to SRP-9001, Sarepta’s investigation gene therapy for Duchenne muscular dystrophy, outside the U.S.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
As part of strategic refocusing, AstraZeneca sold the rights to two cancer drugs in several countries in Europe, Africa and other countries to Juvisé Pharmaceuticals.
The GOOD DESIGN Awards is the oldest and most prestigious global awards program for design excellence and design innovation.
At the Drug Development Unit at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust in London, the first patient in Phoenix’s first in human “ACTivate Trial” has received ACT® in combination with chemotherapy for treatment of hepatic metastases associated with colorectal and pancreatic cancer.
PRESS RELEASES